Abstract
The oral cavity is an accessible site for vaccination, but its sublingual and buccal sites have limited vaccine uptake. Here we show that flat tape dental floss can deliver vaccines through the junctional epithelium of the gingival sulcus, exploiting its naturally leaky properties. Floss-based vaccination delivered protein, inactivated virus, peptide-presenting immunogenic nanoparticles and messenger RNA. In mice, gold nanoparticles functionalized with a peptide derived from the ectodomain of the transmembrane matrix 2 protein of human influenza virus stimulated local lymph nodes, increased CD4+T cells in lymph nodes, lungs and spleen, and boosted antibody-secreting cells in the bone marrow. Floss-based immunization induced strong and sustained immune activation across multiple organs, robust systemic and mucosal antibody responses, and durable protection against lethal influenza infection, independent of age, food and liquid consumption. Floss-based vaccination was superior to sublingual and comparable with intranasal vaccination. In human participants, fluorescent dye delivered via floss picks effectively reached gingival sulcus, supporting clinical feasibility.
These findings establish floss-based vaccination as a simple, needle-free strategy that enhances vaccine delivery and immune activation compared with existing mucosal immunization methods.
Engineers transform dental floss into needle-free vaccine
New method places inactivated viruses directly into mice’s gums
Floss-based vaccination targets the gingival sulcus for mucosal and systemic immunization
Center for Infectious Disease Research and Policy said:At a time when federal officials are calling into question the safety and necessity of COVID-19 vaccines, the mRNA COVID vaccine version used this past season showed no elevated risk of any of the 29 serious adverse events that researchers in Denmark assessed.
The nationwide cohort study, published this week in JAMA Network Open, included 1,585,883 people (54% female), of whom 1,012,400 (64%) received the updated mRNA COVID vaccines containing the JN.1 lineage.
The scientists included all people eligible last season to receive the vaccine—everyone 65 or older and anyone in a high-risk group—who had already received three or more COVID vaccine doses.
No increased risk of 29 adverse events
The investigators assessed for serious side effects for 28 days after vaccine receipt.
"We analyzed 29 adverse outcomes adapted from prioritized lists of adverse events of special interest to COVID-19 vaccines," they wrote. "Each adverse event was analyzed separately."
The Government is to deny six million pensioners Covid jabs this winter.
The rollout will be restricted to only the most vulnerable groups, and the vaccines will not be offered to NHS and care workers.
Only people over the age of 75, those living in care homes and others who are immunosuppressed will be eligible for free vaccines.
The Telegraph? political? surely notThe framing by the Telegraph criticising Labour for a decision made by the JCVI months ago seems a little political…
Shingles vaccine
A shingles vaccine is available on the NHS for:
- people who turned 65 on or after 1 September 2023
- people aged 70 to 79 who have not yet been vaccinated
- people aged 50 and over with a severely weakened immune system
For the development of advice relating to COVID-19 vaccination from autumn 2025, JCVI has resumed the use of a standard cost-effectiveness assessment
There is some other weird thing going on in the UK with regards the shingles vaccination making some people only eligible over 70 but others over 65 or something(?)
eta:
this
The framing by the Telegraph criticising Labour for a decision made by the JCVI months ago seems a little political…
There is some other weird thing going on in the UK with regards the shingles vaccination making some people only eligible over 70 but others over 65 or something(?)
Can you pay out of pocket in the UK to get the shots if you want them?